|
RNF168 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.4485083939303E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.16590004317629E-09 |
| Normal-vs-Stage2 |
2.16900000005182E-06 |
| Normal-vs-Stage3 |
3.03809977175717E-10 |
| Normal-vs-Stage4 |
5.48860001892137E-09 |
| Stage1-vs-Stage2 |
8.860000E-01 |
| Stage1-vs-Stage3 |
2.613600E-01 |
| Stage1-vs-Stage4 |
1.506640E-01 |
| Stage2-vs-Stage3 |
5.152800E-01 |
| Stage2-vs-Stage4 |
3.553800E-01 |
| Stage3-vs-Stage4 |
7.015200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.8783978512954E-11 |
| Normal-vs-AfricanAmerican |
2.855100E-03 |
| Normal-vs-Asian |
6.20150000019137E-07 |
| Caucasian-vs-AfricanAmerican |
2.892400E-01 |
| Caucasian-vs-Asian |
7.123200E-01 |
| AfricanAmerican-vs-Asian |
2.482600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.81617001624591E-12 |
| Normal-vs-Female |
2.20680029805465E-10 |
| Male-vs-Female |
1.396390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.23929999993078E-08 |
| Normal-vs-Age(41-60Yrs) |
9.64828217320246E-12 |
| Normal-vs-Age(61-80Yrs) |
2.68989996943247E-09 |
| Normal-vs-Age(81-100Yrs) |
1.026410E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.605020E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.407000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.121200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.250600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.376800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.042400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.091500E-02 |
| Classical-VS-Follicular |
3.175900E-03 |
| Classical-VS-Other |
5.318000E-02 |
| Classical-VS-Normal |
1.03359999448216E-08 |
| Tall-VS-Follicular |
8.027000E-01 |
| Tall-VS-Other |
3.690600E-01 |
| Tall-VS-Normal |
9.75739999908853E-08 |
| Follicular-VS-Other |
3.222800E-01 |
| Follicular-VS-Normal |
3.60059759785258E-11 |
| Other-VS-Normal |
2.181200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.13380424440857E-11 |
| Normal-vs-N1 |
1.12760001336198E-09 |
| N0-vs-N1 |
2.318800E-01 |
|
|
